Spotlight on bevacizumab and its potential in the treatment of malignant pleural mesothelioma: the evidence to date
PA Levin, JE Dowell - OncoTargets and therapy, 2017 - Taylor & Francis
Malignant pleural mesothelioma (MPM) is a rare, but aggressive cancer. Surgery and
radiation offer limited benefit, and systemic chemotherapy remains the primary treatment …
radiation offer limited benefit, and systemic chemotherapy remains the primary treatment …
Spotlight on bevacizumab and its potential in the treatment of malignant pleural mesothelioma: the evidence to date
PA Levin, JE Dowell - OncoTargets and Therapy, 2017 - dovepress.com
Malignant pleural mesothelioma (MPM) is a rare, but aggressive cancer. Surgery and
radiation offer limited benefit, and systemic chemotherapy remains the primary treatment …
radiation offer limited benefit, and systemic chemotherapy remains the primary treatment …
Spotlight on bevacizumab and its potential in the treatment of malignant pleural mesothelioma: the evidence to date.
PA Levin, JE Dowell - Oncotargets and Therapy, 2017 - europepmc.org
Malignant pleural mesothelioma (MPM) is a rare, but aggressive cancer. Surgery and
radiation offer limited benefit, and systemic chemotherapy remains the primary treatment …
radiation offer limited benefit, and systemic chemotherapy remains the primary treatment …
Spotlight on bevacizumab and its potential in the treatment of malignant pleural mesothelioma: the evidence to date
PA Levin, JE Dowell - OncoTargets and Therapy, 2017 - search.proquest.com
Malignant pleural mesothelioma (MPM) is a rare, but aggressive cancer. Surgery and
radiation offer limited benefit, and systemic chemotherapy remains the primary treatment …
radiation offer limited benefit, and systemic chemotherapy remains the primary treatment …
Spotlight on bevacizumab and its potential in the treatment of malignant pleural mesothelioma: the evidence to date
PA Levin, JE Dowell - OncoTargets and therapy, 2017 - pubmed.ncbi.nlm.nih.gov
Malignant pleural mesothelioma (MPM) is a rare, but aggressive cancer. Surgery and
radiation offer limited benefit, and systemic chemotherapy remains the primary treatment …
radiation offer limited benefit, and systemic chemotherapy remains the primary treatment …
[PDF][PDF] Spotlight on bevacizumab and its potential in the treatment of malignant pleural mesothelioma: the evidence to date
PA Levin - OncoTargets and Therapy, 2017 - scienceopen.com
Malignant pleural mesothelioma (MPM) is a rare, but aggressive cancer. Surgery and
radiation offer limited benefit, and systemic chemotherapy remains the primary treatment …
radiation offer limited benefit, and systemic chemotherapy remains the primary treatment …
Spotlight on bevacizumab and its potential in the treatment of malignant pleural mesothelioma: The evidence to date
PA Levin, JE Dowell - OncoTargets and Therapy, 2017 - utsouthwestern.elsevierpure.com
Malignant pleural mesothelioma (MPM) is a rare, but aggressive cancer. Surgery and
radiation offer limited benefit, and systemic chemotherapy remains the primary treatment …
radiation offer limited benefit, and systemic chemotherapy remains the primary treatment …
[HTML][HTML] Spotlight on bevacizumab and its potential in the treatment of malignant pleural mesothelioma: the evidence to date
PA Levin, JE Dowell - OncoTargets and therapy, 2017 - ncbi.nlm.nih.gov
Malignant pleural mesothelioma (MPM) is a rare, but aggressive cancer. Surgery and
radiation offer limited benefit, and systemic chemotherapy remains the primary treatment …
radiation offer limited benefit, and systemic chemotherapy remains the primary treatment …
Spotlight on bevacizumab and its potential in the treatment of malignant pleural mesothelioma: the evidence to date.
PA Levin, JE Dowell - OncoTargets & Therapy, 2017 - search.ebscohost.com
Malignant pleural mesothelioma (MPM) is a rare, but aggressive cancer. Surgery and
radiation offer limited benefit, and systemic chemotherapy remains the primary treatment …
radiation offer limited benefit, and systemic chemotherapy remains the primary treatment …
[PDF][PDF] Spotlight on bevacizumab and its potential in the treatment of malignant pleural mesothelioma: the evidence to date
PA Levin - OncoTargets and Therapy, 2017 - pdfs.semanticscholar.org
Malignant pleural mesothelioma (MPM) is a rare, but aggressive cancer. Surgery and
radiation offer limited benefit, and systemic chemotherapy remains the primary treatment …
radiation offer limited benefit, and systemic chemotherapy remains the primary treatment …